SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2008 / Cilt: 8 - Sayı: 2

Metabolik sendromu bulunan hastalarda artmış lipoprotein (a) düzeyi: Erken ateroskleroz gelişimi için bir risk faktörü olabilir mi?

Increased lipoprotein (a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis?

Taner ULUS
Aylin YILDIRIR
Bülent ÖZİN
Mehmet E. KORKMAZ
İlyas ATAR
Alp AYDINALP
Haldun MÜDERRİSOĞLU
Hüseyin BOZBAŞ
Serpil EROĞLU
Bahar PİRAT
Pages
111–115
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As expected, the prevalence of hypertension (85.4% vs 55.6%, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It is well known that patients with metabolic syndrome (MS) have a greater risk of developing coronary artery disease (CAD).
📊
Key Findings & Data:Methods: We enrolled 355 consecutive patients from our outpatient cardiology clinic into this cross-sectional, controlled study-186 with MS and 169 without MS, according to the Adult Treatment Panel III criteria.
💡
Conclusion & Impact:As expected, the prevalence of hypertension (85.4% vs 55.6%, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It is well known that patients with metabolic syndrome (MS) have a greater risk of developing coronary artery disease (CAD). However, the association of novel coronary risk factors with MS has not been well established. In this study, we sought to investigate the association of lipoprotein (a) [Lp(a)], homocysteine (Hcy), uric acid, and C-reactive protein (CRP) levels with MS. Methods: We enrolled 355 consecutive patients from our outpatient cardiology clinic into this cross-sectional, controlled study-186 with MS and 169 without MS, according to the Adult Treatment Panel III criteria. Serum Hcy, Lp(a), uric acid, and CRP levels were determined and compared between the groups. Results: The groups were homogenous with regard to age, sex, and other demographic variables (all p>0.05). As expected, the prevalence of hypertension (85.4% vs 55.6%, p

Özet

Metabolik sendromu (MS) bulunan hastalar artmış koroner arter hastalığı (KAH) riskine sahiptirler. Yeni tanımlanan koroner risk faktörleri ile MS arasındaki ilişki net olarak bilinmemektedir. Bu çalışmada MS olan ve olmayan hastalarda lipoprotein (a) [Lp(a)], homosistein (Hcy), ürik asid ve C-reaktif protein (CRP) düzeylerinin ölçülmesi amaçlandı. Yöntemler: Kesitsel, kontrollü olarak planlanan çalışmaya hastanemiz kardiyoloji kliniğine ayaktan başvuran 355 hasta (186 MS, 169 kontrol) dahil edildi. MS ATP III kriterlerine göre tanımlandı. Serum Lp(a), Hcy, ürik asid ve CRP düzeyleri ölçülerek gruplar arasında karşılaştırıldı. Bulgular: Gruplar yaş, cinsiyet ve diğer demografik özellikler açısından benzer idi (p >0.05). Bekleneceği üzere hipertansiyon (%85.4 ve %55.6, p

🔖

Cite This Article

ULUS, T., YILDIRIR, A., ÖZİN, B., KORKMAZ, M. E., ATAR, İ., AYDINALP, A., MÜDERRİSOĞLU, H., BOZBAŞ, H., EROĞLU, S., PİRAT, B. (2022). Metabolik sendromu bulunan hastalarda artmış lipoprotein (a) düzeyi: Erken ateroskleroz gelişimi için bir risk faktörü olabilir mi?. Anadolu Kardiyoloji Dergisi, Cilt: 8 - Sayı: 2, 111–115. https://ajindex.com/articles/437084

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002; 106: 3143-421
  2. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32
  3. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998; 44: 2301-6
  4. Luc G, Bard JM, Arvelier D, Ferrieres J, Evans A, Amouyel P, et al. PRIME Study Group. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002; 163: 377-84
  5. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57
  6. Yılmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Toruner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258-63
  7. Wassef N, Sidhom G, Zakareya el-K, Mohammed el-K. Lipoprotein(a) in android obesity and NIDDM. Diabetes Care 1997; 20: 1693-6
  8. Akanji AO, al-Shayji IA, Kumar P. Metabolic and antropometric determinants of serum Lp(a) concentrations and Apo(a) polymorphism in a healthy Arab population. Int J Obes Relat Metab Disord 1999; 23: 855-62
  9. Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, et al. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. Am J Epidemiol 1995; 141: 815-21
  10. De Pergola G, Giorgino F, Cospite MR, Giagulli VA, Cignarelli M, Ferri G, et al. Relation between sex hormones and serum lipoprotein and lipoprotein(a) concentrations in premenopausal obese women. Arterioscler Thromb 1993; 13: 675-9
  11. Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: The Framingham Heart Study. Circulation 1994; 90: 1688-95
  12. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and